In clinical practice, caring for a diabetes in aging population goes far beyond optimizing hemoglobin A1C. While glycemic control remains central, older adults with diabetes often face unique challenges such as sarcopenia, increased risk of falls, and progressive loss of functional independence. How can clinicians proactively identify these risks and …

In clinical practice, the link between sleep apnea diabetes screening and improved patient outcomes is becoming increasingly clear. Obstructive sleep apnea (OSA) is both a contributor to and a consequence of poor glycemic control, yet it remains under‑recognized in diabetes management. If clinicians fail to screen for sleep apnea in …

Prediabetes affects a striking proportion of adults worldwide, creating a crucial window for intervention before type 2 diabetes develops. While medications like metformin are frequently considered for high-risk individuals, evidence from large clinical trials shows that lifestyle-based strategies — especially the National Diabetes Prevention Program — can dramatically reduce the …

Exercise is a cornerstone of type 2 diabetes care, yet clinicians often struggle with translating broad guidelines into practical, individualized “exercise prescriptions.” The focus keyword in this article, exercise prescription for type 2 diabetes, reflects a high‑intent search term that clinicians, diabetes educators, and patients frequently use when seeking actionable …

Early in training, many clinicians learn the classic “eye–kidney–foot” framework for recognizing and managing complications of diabetes. However, as science advances, the range of recognized consequences of diabetes—and opportunities for earlier intervention—continues to broaden. Today, the concept of diabetes complications screening must evolve to include conditions such as metabolic dysfunction–associated …

Clinicians and care teams are increasingly focused on GLP‑1 receptor agonists, but SGLT2 inhibitors and metformin in diabetes management remain foundational in achieving comprehensive, evidence‑based outcomes. While GLP‑1 therapies generate headlines for weight loss and glucose control, 2025 guidelines still strongly emphasize the cardioprotective and renoprotective benefits of SGLT2 inhibitors …

Living with type 2 diabetes often means managing more than just blood glucose. For many patients, conditions like cardiovascular disease, chronic kidney disease, or depression take center stage in their care plan. When diabetes isn’t the main problem, how do you keep glucose control on track without compromising treatment for …

For decades, clinicians have relied on A1C as the primary benchmark for diabetes control. Yet many patients and providers now wonder: does a single quarterly number truly reflect daily glucose fluctuations and risks? As continuous glucose monitoring (CGM) becomes more accessible, the metric known as Time in Range (TIR) has …

Could continuous glucose monitoring (CGM) soon become the norm in primary care? Once considered a specialty tool reserved for endocrinologists, CGM is now recommended far earlier in diabetes treatment — even for patients with type 2 diabetes on basal insulin alone. Despite these guideline shifts, primary care adoption has lagged. …

Could the conventional “lifelong treatment” model for type 2 diabetes be rethought? Recent trials suggest that short‑term intensive therapy may offer more than transient glycemic control—it might trigger lasting remission in newly diagnosed patients. Such interventions, combining aggressive pharmacologic therapy or insulin with lifestyle change, show potential to preserve β‑cell …